Royal DSM

Royal DSM is engaged in the creation of products and services in Life Sciences and Materials Sciences. Co.'s products and services are used globally in range of markets and applications in healthcare, pharmaceutical automotive and chemicals sectors. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrics and electronics, life protection and housing. The activities of Co. are grouped into four clusters: Nutrition, Pharma, Performance Materials and Polymer Intermediates.
  • TickerDSM
  • ISINNL0000009827
  • ExchangeEuronext Amsterdam
  • SectorChemicals
  • CountryNetherlands

Analysts

Alan Vandenberghe ...
  • Bart Cuypers
  • Lenny Van Steenhuyse
  • Ruben Devos
  • Sandra Cauwenberghs
  • Wim Hoste

KBC Securities Morning Note 8-11-2018 BAMNB NA, BBED NA, BPOST BB, DSM NA, KDS NA, RTL BB, SOLB BB

BAM Group: Good 9M18 revenues yet softer result and TWC Beter Bed Holding: Waking up from a beauty sleep bpost: Ebitda ex. one-off 13% below exp, outlook confirmed DSM: Sweetener JV with Cargill Kiadis: 3 senior hires to support commercialisation ATIR101 RTL Group: First look – Q3 results in line, guidance confirmed Solvay: 3Q REBITDA +3.8%, FY guidance range narrowed Dynamic Top Pick List: Adding Beter Bed Holding to Dynamic Top Pick List

Valérie GASTALDY

Short term view - DSM : The recovery is a consolidation.

The trend is bearish. The recovery is a consolidation. The fall might resume toward €75.61. The background trend would be questioned should prices rise above €93.04.

Valérie GASTALDY

Analyse court terme - DSM : La reprise est une consolidation.

La tendance est baissière. La reprise est une consolidation. La baisse risque de reprendre jusqu'à 75,61 €. La tendance de fond serait remise en cause en cas de franchissement de 93,04 €.

Nurhayati Wan

Royal DSM NV

Nurhayati Wan

Royal DSM NV

Alan Vandenberghe ...
  • Bart Cuypers
  • Lenny Van Steenhuyse
  • Ruben Devos
  • Sandra Cauwenberghs
  • Wim Hoste

KBC Securities Morning Note 8-11-2018 BAMNB NA, BBED NA, BPOST BB, DSM NA, KDS NA, RTL BB, SOLB BB

BAM Group: Good 9M18 revenues yet softer result and TWC Beter Bed Holding: Waking up from a beauty sleep bpost: Ebitda ex. one-off 13% below exp, outlook confirmed DSM: Sweetener JV with Cargill Kiadis: 3 senior hires to support commercialisation ATIR101 RTL Group: First look – Q3 results in line, guidance confirmed Solvay: 3Q REBITDA +3.8%, FY guidance range narrowed Dynamic Top Pick List: Adding Beter Bed Holding to Dynamic Top Pick List

Rob Hales

Morningstar | Nutrition Powers Ahead for Koninklijke DSM in 3Q but Materials Outlook Uncertain; Shares Overvalued

No-moat Koninklijke DSM reported third-quarter EBITDA of EUR 406 million, up 11% over 2017 or 7% excluding the temporary vitamin effect. Results were broadly in line with our view and consensus. Trends remain positive in nutrition, while the materials segment appears to be softening with volumes declining 2% in the quarter. We don’t expect to make a material change to our EUR 66 fair value estimate. At current levels, the shares remain overvalued. In the nutrition business, around EUR 15 million in abnormal profits were recorded due to the BASF citral force majeure. This should be the final q...

Rob Hales

Nutrition Powers Ahead for Koninklijke DSM in 3Q but Materials Outlook Uncertain; Shares Overvalued

No-moat Koninklijke DSM reported third-quarter EBITDA of EUR 406 million, up 11% over 2017 or 7% excluding the temporary vitamin effect. Results were broadly in line with our view and consensus. Trends remain positive in nutrition, while the materials segment appears to be softening with volumes declining 2% in the quarter. We don’t expect to make a material change to our EUR 66 fair value estimate. At current levels, the shares remain overvalued. In the nutrition business, around EUR 15 milli...

Alan Vandenberghe ...
  • Bart Cuypers
  • Cedric Duinslaeger
  • Jason Kalamboussis
  • Ruben Devos
  • Sandra Cauwenberghs
  • Wim Hoste

KBC Securities Morning Note 31-10-2018 AGS BB, BFIT NA, DSM NA, EURN BB, GVNV NA, HEIJM NA, MITRA BB, PNL NA, REC BB, TNET BB, WKL NA

Ageas: Sells its 33% in Cardif Lux Vie to BNP Paribas Cardif Basic-Fit: On track to reach FY guidance DSM: 3Q REBITDA +11% Euronav: Conf Call Feedback GrandVision: 3Q18 in line, guidance reiterated Heijmans: 3Q18 business in line, € 10m provision Wintrack II Mithra: Commercialization agreement with Adcock Ingram PostNL: Lowers financial impact from ACM measures Recticel: 3Q revenue -4.1%, FY guidance slightly lowered Telenet: Commercial challenges, guidance raised Wolters Kluwer: 9M18 trading update – On Track

ING
Research Department

Benelux Morning Notes

Air France-KLM: 3Q18 better than expected, outlook cautious Aperam: 3Q18 EBITDA in line, 4Q18 guidance negative Basic-Fit: solid Q3 trading update; improving yield per member DSM: Margin Machine Fugro: Next game-changing news in the OBC market GrandVision: Good quarter confirms outlook Heijmans: Deals with issue, giving share price a floor PostNL: new tariffs for network access to see significant positive impact on cash EBIT Recticel: Profit warning driven by a weak quarter in retail and automotive Royal Dutch Shell: Solid 3Q18 expected Staffing sector: Dutch period 10 - vol flat, rev +4% (was...

1 director bought

A director at Koninklijke Dsm Nv bought 8,300 shares at 90.260EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of...

Nurhayati Wan

Royal DSM NV

Nurhayati Wan

Royal DSM NV

An unfavourable environment weighs on KONINKLIJKE DSM, which sees a downgrade to Slightly Negative

The independent financial analyst theScreener just requalified the general evaluation of KONINKLIJKE DSM (NL), active in the Specialty Chemicals industry. As regards its fundamental valuation, the title still shows 1 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date October 19, 2018, the closing price was EUR 78.64 and its target price was estimated at EUR 74.71.

Nurhayati Wan

Royal DSM NV

null

Nurhayati Wan

Royal DSM NV

Expert Corporate Governance Service (ECGS)

Etude de l'AG du 03/0/2017

Under agenda item 5a, it is proposed to amend the Articles of Association in relation to the Cumulative Preference Shares A. The changes are such that the dividend percentage of the Preference Shares will every year be based upon the dividend yield of the ordinary shares in the preceding year. We have no concerns over the proposed amendment, we consider the proposed return on the Cumprefs A to be fair. We recommend approval.Under agenda item 10b, it is proposed to authorize the Management Board for a period of 18 months to restrict or exclude the pre-emptive rights allowed to shareholders in r...

Valérie GASTALDY

Short term view - DSM : The recovery is a consolidation.

The trend is bearish. The recovery is a consolidation. The fall might resume toward €75.61. The background trend would be questioned should prices rise above €93.04.

Valérie GASTALDY

Analyse court terme - DSM : La reprise est une consolidation.

La tendance est baissière. La reprise est une consolidation. La baisse risque de reprendre jusqu'à 75,61 €. La tendance de fond serait remise en cause en cas de franchissement de 93,04 €.

Valérie GASTALDY

Short term view - DSM : The trend is bearish.

The trend is bearish. Prices are falling again, but the movement has become hesitant. The next support is at €75.61. The bearish trend would be challenged above €93.04.

Valérie GASTALDY

Analyse court terme - DSM : La tendance est baissière.

La tendance est baissière. Les prix baissent à nouveau, mais le mouvement est devenu hésitant. Le prochain support est à 75,61 €. La tendance baissière serait remise en cause au-dessus de 93,04 €.

Valérie GASTALDY

Medium term view - DSM : The trend is bullish.

The trend is bullish. The recent fall is getting more vigorous. The next support is at €75.29. A break below €75.29 would challenge the trend.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch